Current international risk stratification is based on the patient’s age, tumour site, tumour size, PAX-FOXO1 fusion status, presence of nodal involvement or metastatic disease and the Intergroup Rhabdomyosarcoma Studies (IRS) post-surgical group staging [14, 15, 35–37]. This evidence concerns the gene FOXO1 and rhabdomyosarcoma.